- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Audrey Sternberg | Authors
Articles
Application for Brexucabtagene Autoleucel in B-cell ALL Submitted to FDA for Consideration
April 09, 2021
CD19-directed CAR T-cell therapy brexucabtagene autoleucel will be considered by FDA for indication in adults with B-cell precursor acute lymphoblastic leukemia.
Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer
April 09, 2021
An analysis of real-world outcomes in a cohort of patients treated in mostly community settings showed that palbociclib plus letrozole improved both progression-free and overall survival in women with hormone receptor–positive, HER2-negative metastatic breast cancer.
Recombinant Adenovirus 5 Vaccine Shows Promise Against Castration-Resistance Prostate Cancer
April 08, 2021
A second-generation human adenovirus 5 immunotherapy vaccine has activity in patients with metastatic castration-resistant prostate cancer who are not responding to other available therapies.
Molecular Response by Guardant360 Liquid Biopsy Translates to Clinical Outcomes in NSCLC
April 07, 2021
Screening patients for molecular response using the Guardant360 assay provides an early signal of antitumor activity for pembrolizumab-based treatment of non–small cell lung cancer.
CancerNetwork Honors World Health Day by Looking at Recent Breakthroughs in Cancer Prevention, Screening
April 07, 2021
CancerNetwork® reports on updates in prevention and earlier diagnosis of colorectal, breast, and other cancers.
Umbralisib Activity, Safety in Indolent Lymphomas Demonstrated in Phase 2b Trial
April 06, 2021
Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors.
Investigational RET Inhibitor TPX-0046 Show Preliminary Clinical Activity in NSCLC, MTC
April 06, 2021
In a dose-finding trial, TPX-0046 elicited responses in patients with non–small cell lung cancer and medullary thyroid cancer who were naïve to prior tyrosine kinase inhibitors and whose tumors harbored alterations in RET.
Whole-Genome Sequencing Shows Ability to Identify Progressive Myeloma Precursor
April 06, 2021
A higher mutational load detected by whole-genome sequencing in patients with multiple myeloma precursor conditions was likely predictive of subsequent disease progression.
Cryoablation Technology for Early Breast Cancer Earns Breakthrough Therapy Designation
April 05, 2021
The next-generation cryoablation technology ProSense was granted breakthrough device designation to treat certain patients with T1 breast tumors.
Long-Term OS Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost
April 05, 2021
With more than 5 years of follow-up, results from the SOLO2 trial of olaparib maintenance in relapsed, high-grade serous or endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, were reported and showed superiority of the agent over placebo.